Type 1 diabetes patients who received the psoriasis medication alefacept attained significant improvements in preserved insulin secretion at four hours compared with those in the placebo group, according to a study in The Lancet Diabetes & Endocrinology. Researchers also found patients in the alefacept arm were using less supplementary insulin and were less likely than those in the control group to experience hypoglycemic episodes one year after starting treatment.

Full Story:

Related Summaries